Axalbion
PrivateLast Round
Early Funding
Aug 27, 2024
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Axalbion is a clinical-stage biopharmaceutical company developing novel medicines for the treatment of chronic cough.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Axalbion Comparables
Compare Axalbion with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeRRe Therapeutics | 86% | |
| Seyltx, Inc. | 84% | |
| Nocion Therapeutics | 80% | |
Axalbion Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 27, 2024 |
Axalbion Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Perscitus LLP | Early Funding |
| EPFL Innovation Park | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 309% MoM, reaching 2K.
Axalbion Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Axalbion's valuation, stock price, and market status.